Please assess the completion status of the following clinical trial:

Trial Title: Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~* Voluntary written consent~* Locally advanced or metastatic solid tumors with the exception of primary brain tumor, and have failed or are not eligible for standard of care therapy~* Eastern Cooperative Oncology Group (ECOG) performance status 0-1~* Ability to swallow oral medications~* For women of child-bearing potential, negative serum or urine pregnancy test within 14 days prior to the first study drug administration and use of physician-approved method of birth control from 30 days prior to 30 days following the last study drug administration~* Male participants must be surgically sterile or must agree to use physician-approved contraception during the study and for 30 days following the last study drug administration~* Clinical laboratory values as specified in the protocol~* For expansion phase (Arm A) - HER2-/unknown participants will be enrolled~* For expansion phase (Arm B) - HER2+ cancer participants will be enrolled~Exclusion Criteria:~* Diagnosis of primary brain tumor~* Have received prior cancer or other investigational therapy within 2 weeks prior to the first administration of study drug~* Known impaired cardiac function or clinically significant cardiac disease~* Known treatment with systemic corticosteroid within one week prior to the first administration of study drug~* Diabetes mellitus~* Human immunodeficiency virus (HIV) infection~* Known active cardiovascular disease condition as specified in protocol~* Pregnancy (positive serum or urine pregnancy test) or breast feeding~* Malabsorption due to prior gastrointestinal (GI) surgery, GI disease~* Other clinically significant co-morbidities~Please note that there are additional inclusion and exclusion criteria. The study center will determine if you meet all of the criteria.~Site personnel will explain the trial in detail and answer any question you may have if you do qualify for the study. You can then decide whether or not you wish to participate. If you do not qualify for the trial, site personnel will explain the reasons

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MLN0128P 30 mg QW (Type: EXPERIMENTAL): MLN0128 and paclitaxel (MLN0128P): MLN0128 30 mg, capsule, orally, once weekly (QW) + paclitaxel 80 mg/m\^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
- MLN0128P 40 mg QW (Type: EXPERIMENTAL): MLN0128 40 mg, capsule, orally, once a week (QW) + paclitaxel 80 mg/m\^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
- MLN0128P 6 mg QD×3d QW (Type: EXPERIMENTAL): MLN0128 6 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m\^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
- MLN0128P 7 mg QD×3d QW (Type: EXPERIMENTAL): MLN0128 7 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m\^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
- MLN0128P 8 mg QD×3d QW (Type: EXPERIMENTAL): MLN0128 8 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m\^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
- MLN0128P 9 mg QD×3d QW (Type: EXPERIMENTAL): MLN0128 9 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m\^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
- MLN0128P 10 mg QD×3d QW (Type: EXPERIMENTAL): MLN0128 10 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m\^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
- MLN0128P 7 mg QD×5d QW (Type: EXPERIMENTAL): MLN0128 7 mg, capsule, orally, once daily 5 days on/2 days off each week + paclitaxel 80 mg/m\^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
- MLN0128P 8 mg QD×3d QW HER2- (Type: EXPERIMENTAL): MLN0128 8 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m\^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in human epidermal growth factor receptor 2 negative (HER-) cancer participants until disease progression or unacceptable toxicity for up to 1 year in the Expansion Phase.
- MLN0128PH 8 mg QD×3d QW HER2+ (Type: EXPERIMENTAL): MLN0128 + paclitaxel + trastuzumab (MLN0128PH): MLN0128 8 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m\^2, 1 hour infusion, on Days 1, 8 and 15 plus trastuzumab 4 mg/kg loading dose on Day 1 followed by 2 mg/kg, intravenous each week of a 4-week cycle in HER+ cancer participants until disease progression or unacceptable toxicity for up to 1 year in the Expansion Phase.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete